We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Monitor Toxicity, Anti-Cancer Drug Efficacy and Cytokine Response with New Bioluminescent Cytotoxicity Technology
Product News

Monitor Toxicity, Anti-Cancer Drug Efficacy and Cytokine Response with New Bioluminescent Cytotoxicity Technology

Monitor Toxicity, Anti-Cancer Drug Efficacy and Cytokine Response with New Bioluminescent Cytotoxicity Technology
Product News

Monitor Toxicity, Anti-Cancer Drug Efficacy and Cytokine Response with New Bioluminescent Cytotoxicity Technology


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Monitor Toxicity, Anti-Cancer Drug Efficacy and Cytokine Response with New Bioluminescent Cytotoxicity Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Promega Corporation has announced the launch of the CytoTox-Glo™ Cytotoxicity Assay at the 5th annual Screening Europe conference and exhibition. Whether monitoring chemical toxicity, anti-cancer drug efficacy or cytokine response, the CytoTox-Glo Assay is designed to provide a sensitive, simple, luminescent method that allows the user to detect small changes in cell viability.

The assay measures a distinct “dead-cell” protease biomarker released from cells that have lost membrane integrity, a key indicator of cytotoxicity. The assay uses a peptide substrate, that after cleavage by the “dead-cell” protease, releases luciferin. This is a substrate for a proprietary thermostable luciferase (Ultra-Glo™ Recombinant Luciferase).

The luciferase/luciferin reaction produces light in the form of a stable “glow-type” luminescent signal. The intensity of the signal correlates with dead-cell number.

The CytoTox-Glo Assay has a large dynamic range with linearity, providing unprecedented sensitivity in 96-well plates or high-density formats. The high sensitivity and scalability minimizes both the number of cells required and the amount of compound used. Features of this assay are detailed in a talk by Promega.

Advertisement